The pharma company said the drug combined with eltrombopag demonstrated a significant improvement in time to treatment ...

Swiss ministers have met with senior executives of pharmaceutical companies Roche and Novartis to discuss the outlook for the ...

Novartis AG said an experimental medicine helped patients with an autoimmune disease in late-stage studies, offering a boost ...

The overwhelming federal nature of this subject is apparent,” the lawsuit alleges. “States are not free to tinker with ...

Novartis may have abandoned one Sjögren's syndrome asset this year, but it looks like the drugmaker has a winner on its hands ...

A mere 24 hours after Novartis' ianalumab hit the mark in two phase 3 trials in Sjogren's syndrome, the drug has delivered ...

A day after posting a pair of phase 3 wins for the tricky indication of Sjögren's syndrome, the Swiss pharma has unveiled a ...

Swiss drugmaker Novartis has approached U.S. biotech Avidity Biosciences for a potential takeover offer, the Financial Times ...

The state of Maine is being sued by a pharmaceutical company over its discount drug program. Novartis, a New Jersey-based company, is seeking to end Maine’s regulation of the 340B Drug Pricing Program ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

And if you're looking for top dividend-paying companies to put your money in right now, let's consider two excellent ...

Novartis has been evaluating a bid for Avidity, which had a market value of about $5.8bn at market close on Wednesday, and ...